You are here: Home » Companies » Industry
Business Standard

Indian pharma firms renew focus; Dr Reddy's, Cipla eye $100-bn China market

DRL looking to introduce anti-cancer drugs, while Cipla, Wockhardt planning to launch core therapies

Aneesh Phadnis & Sohini Das  |  Mumbai/Ahmedabad 

Approval for generics drug up but US business shrinks for home firms

Dr Reddy’s Laboratories (DRL) is expanding its presence in China, the world’s second-largest pharmaceutical market, where other drug manufacturers such as and are exploring opportunities. The more than $100-billion market is dominated by local drug manufacturers and multinationals and India’s of around $160 million are a fraction of the companies’ sales. But recent changes in regulation allowing quicker product approval and growth opportunities in have been drivers for Indian According to The Pharma Letter website, China’s recently decided to acknowledge foreign trial data and hire more people to speed up drug approvals — moves that could benefit India’s drug manufacturers. “While Indian have traditionally focused on the US and Europe, new regulations in China, which could fast-track approvals for products cleared by the US Food and Drug Administration, could help Indian secure a foothold in the market,” said Sriram Shrinivasan, global emerging markets leader, lifesciences, EY. DRL said it was planning to introduce anti-cancer drugs, while and are planning to launch core therapies such as and respiratory drugs in pharma Source: Pharmaceuticals Export Promotion Council of India “A strong pipeline is in place and this will continue to be strengthened along with the expansion of our field force. Oncology is an area of focus. We are also looking at partnerships to expand our commercial footprint in the market,” said DRL Executive Vice-President M V Ramana. DRL manufactures and sells drugs in in a joint venture with Canada’s Rotam group. The joint venture (JV) has a sales and marketing team covering 5,000 hospitals spread over DRL sells products worth around $20 million in China, according to global health care services firm IQVIA. However, the figure does not include sales of active pharmaceutical ingredients. While DRL has been present in the Chinese market for nearly 20 years, other Indian have had limited success there.

Ranbaxy, which was acquired by in 2014, exited from a JV in and sold its stake to its partners in 2009. Torrent dropped its plans to launch drugs in because of stringent regulatory requirements. In 2013, the firm had initiated talks with a Chinese company but the plan was dropped two years later, a company spokesperson said. Three years ago exited from two investments it had made in But drug manufacturers are preparing to take fresh bets in the market with a focus on core therapies. The operating environment will remain challenging but strong demand and quick approval for innovative products in are an attraction, according to IQVIA. is planning to launch its in and is in talks with local for clinical trials. The company is developing five is keen to make a foray into the respiratory segment through an acquisition or partnership. A spokesperson for the company was not available for comment. “We will explore because it is a very large market for antibiotics,” Chairman Habil Khorakiwala stated. The market in is double that of the US by value and is 25 times bigger in volumes, indicating a huge potential for Wockhardt’s novel drug pipeline. “In we intend to outlicense the We studied the market and found it is too complex for us to market drugs,” Khorakiwala added. Fabrice Egros, Lupin’s president for the Asia-Pacific region, said the company was exploring opportunities for partnerships in However, cultural challenges, along with the fragmented nature of the market, have been seen as hindrances. “Indian have not focused on because of complexities and higher opportunities in markets like and Japan, which are the focus areas after the US,” said D G Shah, secretary-general,

First Published: Wed, February 14 2018. 05:44 IST
RECOMMENDED FOR YOU